According to the WHO 2024 Global Hepatitis Report, viral hepatitis is on the rise and remains the second leading infectious cause of death globally, claiming 1.3 million lives annually, equivalent to tuberculosis. Ten countries account for nearly two-thirds of the global burden of viral hepatitis B and C: China, India, Indonesia, Nigeria, Pakistan, Ethiopia, Bangladesh, Vietnam, The Philippines and the Russian Federation.
The APAC region is disproportionately affected, with 70 per cent of viral hepatitis deaths occurring here. Failure to act swiftly could lead to substantial economic losses, with projected costs of $558 billion for hepatitis B and $62 billion for hepatitis C due to illness and premature mortality, according to the Coalition for Global Hepatitis Elimination report.
WHO has set a goal to eliminate viral hepatitis by 2030, aiming for a 90 per cent reduction in incidence and a 65 per cent reduction in mortality from hepatitis B and C.
Progress so far
Most of the countries in the region have a national hepatitis elimination programme but progress remains somewhat unsatisfactory.
“Viral hepatitis has a devastating impact on South-East Asia and the Western Pacific regions, where an estimated 158 million people live with chronic hepatitis B and 16 million with chronic hepatitis C. Access to treatment for hepatitis B and C remains a challenge in many Asian countries due to cost and healthcare infrastructure limitations. Furthermore, vertical transmission (from mother to child) of hepatitis B is a major concern in the region. Such a heavy prevalence has a profound disruptive effect on society in the region. On top of causing a tragic loss of life, viral hepatitis poses a huge societal and financial burden and drives inequality,” said
Benedetta Nirta, Deputy Director and Fundraising Manager at The Hepatitis Fund, Geneva.
هذه القصة مأخوذة من طبعة BioSpectrum Asia July 2024 من BioSpectrum Asia.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك ? تسجيل الدخول
هذه القصة مأخوذة من طبعة BioSpectrum Asia July 2024 من BioSpectrum Asia.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك? تسجيل الدخول
Prof. Christian Wolfrum to join NTU as Deputy President and Provost
Nanyang Technological University, Singapore (NTU Singapore) has announced that Professor Christian Wolfrum, an eminent biomedical scientist, will be joining the University as the next Deputy President and Provost.
Japan suggests addition of PVA into drugs for strong antitumour activity
Treatment for more advanced and difficult-to-treat head and neck cancers can be improved with the addition of polyvinyl alcohol (PVA), the same ingredient used in children's glue.
"Demand for skilled medtech professionals in the Asia Pacific region is growing rapidly"
2024 saw Japanese medtech firm Olympus receiving approval for the company's first cloud-based AI endoscopy devices in the US and Europe, marking a significant milestone in Olympus' efforts to enhance clinical outcomes and operational efficiency in endoscopy, paving the way to launch its upcoming endoscopy solution, the “Intelligent Endoscopy Ecosystem”.
BeiGene names Giancarlo Benelli as Head of Europe biz
BeiGene, a Hong Kong-headquartered oncology company that intends to change its name to BeOne Medicines Ltd., has announced the appointment of Giancarlo Benelli as Senior Vice President and Head of Europe, effective January 1.
Korea develops innovative injectable adhesive hydrogel for bone regeneration
A research team from South Korea-based Pohang University of Science and Technology or POSTECH's Department of Chemical Engineering and Graduate School of Convergence Science and Technology, along with the Department of Chemical Engineering, has developed an innovative injectable adhesive hydrogel for bone regeneration.
When Clinical Trials Suffer From 'Complicated' Interactions
Diversity in culture, language, and data gathering methods will further increase the difficulty of clinical trials as they become more international, particularly with the growing number of sites being employed across China, Japan, South Korea, and India.
Dr Krishna M Ella receives prestigious INSA India fellowship
Dr Krishna Ella, a distinguished scientist, co-founder and Executive Chairman of Bharat Biotech International, has been recognised with the prestigious India Fellowship of the Indian National Science Academy (INSA) for the year 2025, for his contributions to new knowledge, discoveries, development of new vaccine technologies, noteworthy improvement in existing technologies.
Bruker launches infrared imaging microscope for pharma and life science research
US-based Bruker Corporation has announced the launch of the LUMOS II ILIM, a quantum cascade laser (QCL) based infrared (IR) imaging microscope.
Qiagen increases QIAcuity digital PCR high-order multiplexing capabilities
Qiagen has announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) system with a more than two-fold increase in the number of targets that can be simultaneously analysed from a single biological sample.
Repligen unveils advanced UV-based Variable Pathlength Technology system for biopharma manufacturers
US-based Repligen Corporation has announced the commercial launch of its CTech SoloVPE PLUS System, the most advanced UV-based Variable Pathlength Technology system now available to biopharmaceutical manufacturers.
